Last reviewed 2026-05-20 · How we verify

Vitamin D 3

Vitamin D 3 is a Vitamin/Steroid hormone Small molecule drug developed by Second Affiliated Hospital of Wenzhou Medical University. It is currently FDA-approved for Vitamin D deficiency, Hypocalcemia, Hypoparathyroidism. Also known as: Oleovit D3, Fresenius Kabi, Austria.

Vitamin D3 acts as a steroid hormone precursor that regulates calcium and phosphate homeostasis and modulates immune function through binding to the vitamin D receptor.

Vitamin D3, also known as cholecalciferol, is a small molecule used as an intervention in various clinical trials to study its effects on conditions such as Vitamin D Deficiency, Heart Failure, and Diabetes. It is a supplement used to improve vitamin D status and cardiometabolic health, as seen in a study titled "The Effect of Vitamin D Supplements on Vitamin D Status, Cardiometabolic Health and Immune Defense in Danish Children".

At a glance

Mechanism of action

Vitamin D3 (cholecalciferol) is converted in the liver to 25-hydroxyvitamin D and then in the kidneys to the active form 1,25-dihydroxyvitamin D, which binds to the vitamin D receptor (VDR) in target tissues. This binding regulates gene expression to promote intestinal calcium and phosphate absorption, maintain bone mineralization, and modulate immune cell differentiation and function. VDR activation also influences cell proliferation, differentiation, and apoptosis across multiple cell types.

Approved indications

• Vitamin D deficiency
• Hypocalcemia
• Hypoparathyroidism
• Osteomalacia
• Rickets
• Bone health maintenance

Common side effects

• Hypercalcemia
• Hypercalciuria
• Nausea
• Vomiting
• Constipation
• Weakness

Key clinical trials

• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants (PHASE2)
• Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
• Acute Vitamin D Supplementation on Testosterone in Females (NA)
• PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery" (NA)
• Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients (PHASE2)
• Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older
• Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters
• Vegan Diet and Immune-Inflammatory Outcomes in Asthma and Healthy Adults (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Vitamin D 3 CI brief — competitive landscape report
• Vitamin D 3 updates RSS · CI watch RSS
• Second Affiliated Hospital of Wenzhou Medical University portfolio CI

Frequently asked questions about Vitamin D 3

Related

• Drug class: All Vitamin/Steroid hormone drugs
• Target: All drugs targeting Vitamin D receptor (VDR)
• Manufacturer: Second Affiliated Hospital of Wenzhou Medical University — full pipeline
• Therapeutic area: All drugs in Endocrinology, Bone Health, Immunology
• Indication: Drugs for Vitamin D deficiency
• Indication: Drugs for Hypocalcemia
• Indication: Drugs for Hypoparathyroidism
• Also known as: Oleovit D3, Fresenius Kabi, Austria

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing